NASDAQ:PYPD PolyPid Q2 2026 Earnings Report $4.37 +0.29 (+7.11%) Closing price 04:00 PM EasternExtended Trading$4.34 -0.04 (-0.80%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PolyPid EPS ResultsActual EPSN/AConsensus EPS -$0.34Beat/MissN/AOne Year Ago EPSN/APolyPid Revenue ResultsActual RevenueN/AExpected Revenue$0.30 millionBeat/MissN/AYoY Revenue GrowthN/APolyPid Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile PolyPid Earnings HeadlinesPolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026July 30 at 8:30 AM | quiverquant.comQPolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026July 30 at 8:00 AM | globenewswire.comAmerica's solution to universal basic income already exists.Elon Musk says there will be no poverty in the future and that money won't matter in ten years. Until that day arrives, one existing program already pays out on a similar promise. The Patriot Income Plan issues 42 payouts a year - roughly once a week - funded by partnerships that control America's critical infrastructure, not tax dollars. Enrollees have historically received a 10 percent annual yield, and since 2020 the average partnership has produced 20 percent average annual gains.July 30 at 1:00 AM | Freedom Financial (Ad)PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀July 29 at 8:30 AM | globenewswire.comHC Wainwright Has Positive Outlook for PolyPid Q2 EarningsJuly 25, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for PolyPid (NASDAQ:PYPD)July 23, 2026 | americanbankingnews.comSee More PolyPid Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PolyPid? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PolyPid and other key companies, straight to your email. Email Address About PolyPidPolyPid (NASDAQ:PYPD) Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients. Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia. OncoTears has received marketing authorization in select countries of the former CIS, and the company is advancing regulatory filings for its lead assets in the United States and European Union. Research and clinical operations are conducted in Israel, with strategic collaborations established to support commercialization efforts and late‐stage clinical trials in multiple geographies. Under the leadership of co-founder and Chief Executive Officer Yoel Hakim, PolyPid’s management team brings together expertise in polymer chemistry, pharmacology and regulatory affairs. As a Nasdaq‐listed entity, the company remains focused on driving its clinical programs toward pivotal studies, while exploring new therapeutic applications of its mucus‐penetrating delivery platform to address unmet medical needs across a range of mucosal diseases.View PolyPid ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft Just Flipped the AI Spending Narrative OvernightQualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?Can Starbucks Keep This Turnaround Going? The Latest Results Say YesTesla: After a Rough Quarter, 2 Very Different Futures Come Into FocusMeta’s Earnings Show Why Wall Street Is Losing Patience With AI SpendingWhy NXP Semiconductors Could Be the AI Stock Everyone Is MissingPalantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
